Introduction

Acute upper gastrointestinal (UGI) bleeding is a common medical emergency among the elderly. There is limited data on the management and outcomes of non-variceal UGI bleeding in the elderly in India.

Aims & Methods

We aimed to study clinical presentation, endoscopic findings, and outcomes in elderly patients with acute non-variceal UGI bleeding. All elderly patients (≥ 60 years of age) who presented with acute UGI bleed and were admitted for the same from 2021 to 2022 were retrospectively analysed. Baseline characteristics, blood transfusions before and after endoscopy, endoscopic diagnosis and therapy, AIMS65 score, complete Rockall score, and outcomes such as in-hospital re-bleeding and mortality were recorded.

Results

Of the 399 patients who had acute non-variceal UGI bleed, 309 patients aged <60 years were excluded. Of the 90 patients studied, the mean age of presentation was 69.8 ± 7.35 years, with 81.1% males. The most common presentation was melena (30%). Forty-one (45.5%) patients had a history of antiplatelet and anticoagulant use. The most common endoscopic finding was gastric ulcer (54.4%), followed by duodenal ulcer (22.2%), gastroesophageal junction ulcer (7.7%), Mallory-Weiss tear (6.6%), duodenal diverticular bleed (2.2%). The majority of ulcers were Forrest III (43.3%), followed by Forrest IIa (23.3%) and IIc (18.3%). Around 65% of patients with non-variceal UGI bleeds did not require endotherapy. Dual endotherapy was done in 25.5.5% of patients. Triple endotherapy was done in two patients. AIMS65 score was 1 in 50% of patients and 2 in 24.5% of patients. The majority (81.1%) of patients had a complete Rockall score of 3-7, indicating a moderate risk of re-bleeding and mortality. All the 90 patients were discharged without any mortality.

Conclusion

Our study showed that gastric ulcer was the most common cause of acute non-variceal UGI bleeding in the elderly, and melena was the most common presentation. Early endoscopic therapy may reduce blood transfusion requirements, in-hospital re-bleeding, and mortality.

Introduction

H. pylori infection has affected approximately 50% of the world’s population with the rates being higher in developing countries than in developed ones. Conventional proton-pump inhibitors (PPIs) have been used as first-line treatment for this condition. However, potassium competitive acid blockers (PCABs) were recently developed which may offer beneficial effects than PPIs.

Aims & Methods

This meta-analysis aims to assess the effectiveness of Potassium competitive acid-blocker against Proton pump inhibitors for the eradication of H. pylori among adults with H. pylori infection.
Electronic search of randomized controlled trials comparing H pylori eradication rate of P-CAB and PPI-based therapy was done. Quality assessment used the Modified Cochrane risk-of-bias tool, and statistical analysis was performed using ReviewManager 5.4.1

Results

Fifteen RCTs with 4129 participants who received H pylori eradication therapy comparing potassium competitive acid blockers (Tegoprazan, Vonoprazan, and YH808) with proton pump inhibitors were analyzed. H. pylori eradication rate of potassium competitive acid blocker-based therapy was higher than that of PPI-based triple therapy RR 1.04, CI 1.10-1.18, P < 0.05. Subgroup analysis showed that PCABs based regimens had significantly higher eradication rates than PPI in treatment naive patients (RR 1.14, 95% CI 1.1-1.18, pP < 0.05 ) and that Vonoprazan based regimen in particular had superior eradication rates compared to PPI based regiments (RR 1.16 95% CI 1.12-1.20 P < 0.05). No significant differences were seen between the Tegoprazan and YH4808 groups compared to the PPI group. Adverse events were also lower in the PCAB group compared to the PPI group.

Conclusion

A significant challenge that is being faced by current PPIs include nocturnal acid reflux despite treatment with twice daily PPI, and additional dosage of H2-receptor blocker at bedtime which deters successful control of gastritis under PPI treatment.Our study shows that potassium competitive acid blockers are effective and have significantly higher eradication rates compared to PPI, with lower incidence of adverse events.

References

Yu, K. et al. (2020). Randomized clinical trial: tegoprazan, a novel potassium competitive acid blocker or lansoprazole in the treatment of gastric ulcer. Aliment PHarmacol Ther. 2020 Sept;52 (5);789-797
Tan, N. et al. (2023). Efficacy and safety of keverprazan compared with lansoprazole win the treatment of duodenal ulcer: a phase III, randomized double blind multicenter trial. Clinical and Translational Gastroenterology. 2023 Jul; 14(7)
Kim, J. et al. (2023). Efficacy of tegoprazan-based bismuth quadruple therapy compared with bismuth quadruple therapy for Helicobacter pylori infection: A randomized, double-blind, active-controlled study. Helicobacter. 2023 June; 28(3)
Zhou, S. et al. (2023). Keverprazan, a novel potassium-competitive acid blocker: Single ascending dose safety, tolerability, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. European Journal of Pharmacetucial Sciences 190(1)2023;2-12
Zhou, B. et al. (2023). Vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication: A systematic review and meta-analysis of randomized controlled trials. Saudi J Gastroenterol.2023 Nov-Dec; 29(6): 347–357.
Yang, C. et al. (2022). Effectiveness and safety of vonoprazan-based regimen for Helicobacter pylori eradication: A meta-analysis of randomized clinical trials. J Clin Pharm Ther. 2022 Jul;47(7):897-904

Disclosure

authors have no conflict of interest

Introduction

Endoscopic papillectomy (EP) for duodenal ampullary tumors is primarily performed for lesions confined to the papilla, particularly adenomatous changes. However, early complications such as bleeding (0-21.6%), pancreatitis (0-23.1%), and perforation (0-8.3%) occur at relatively high rates. Post-EP bleeding, due to anatomical characteristics of the ampulla of Vater, can be challenging to manage and may worsen, making it critical to identify factors associated with this complication to reduce its frequency.

Aims & Methods

The study aimed to investigate the factors associated with post-endoscopic papillectomy bleeding in patients with ampullary tumors. This study included 39 patients (39 lesions), excluding residual and accessory ampullary lesions, who underwent EP at our institution between March 2011 and October 2024. We evaluated univariate analysis and SHAP values based on tree-based models for several factors related to post-EP bleeding. Hyperparameters of each model were optimized by optuna, and those models were trained with the Python package scikit-learn (version 1.3.0).

Results

The cohort included 1 adenocarcinoma, 32 adenomas, 1 neuroendocrine neoplasm, and 5 cases of ampullary inflammation, with a mean age of 66.7 years (23 males, 16 females). Patient factors included: The American Society of Anesthesiologists (ASA) Physical Status Classification I/II/III in 5/21/13 participants, median Charlson Comorbidity Index (CCI) of 1 (range 0-7), 15 cases with a history of alcohol consumption, median Brinkman Index of 100 (range 0-1680), median total bilirubin of 0.7 mg/dL (range 0.2-2.1), median serum amylase of 80 IU/L (range 36-296), median platelet count of 198,000/μL (range 113,000-494,000), median PT-INR of 0.98 (range 0.86-1.14), median APTT of 28.7 seconds (range 23.0-39.4), median CEA of 1.9 ng/mL (range 0.3-12.8), and median CA19-9 of 7.7 U/mL (range 0.8-76.4). Antithrombotic agents were used in 4 participants (1 on low-dose aspirin, 1 on clopidogrel, and 2 on direct oral anticoagulants), and periampullary diverticula were observed in 3 cases. Median tumor size was 10.3 mm (range 2.0-45.0). Procedural factors included a median total procedure time of 56 minutes (range 23-230), with 36 cases receiving endoscopic biliary stenting and 38 cases receiving endoscopic pancreatic duct stenting. The electrosurgical units ICC200/VIO300D/VIO3 were used in 9/19/11 cases, respectively. Protease inhibitors were used in 9 participants, NSAID suppositories (25mg/50mg) in 5/24 cases, and local hemostatic measures included epinephrine spray in 8 cases, thrombin spray in 8 cases, and hemostatic peptide solutions in 5 cases. Clipping for ulcer after resection was performed in 33 cases. Post-EP bleeding within 30 days occurred in 12 cases (30.8%), including 9 moderate and 3 severe cases. Univariate analysis revealed that a history of alcohol consumption was significantly associated with post-EP bleeding (Odds ratio [OR] 2.33, 1.14-4.79, P = 0.02). Feature importance was evaluated using the mean absolute SHAP values across all participants. In the Random Forest model, the top contributing features were CA19-9 (mean |SHAP| = 0.026), CCI (mean |SHAP| = 0.024), and a history of alcohol consumption (mean |SHAP| = 0.023). In contrast, the XGBoost model identified tumor size (mean |SHAP| = 0.315), a history of alcohol consumption (mean |SHAP| = 0.244), and platelet count (mean |SHAP| = 0.198) as the most important features.

Conclusion

In our cohort, a history of alcohol consumption is a robust factor associated with post-endoscopic papillectomy bleeding.